Evidence map›Paper›PMID 38690000›Full record

ArticleHeliyon2024

Distinguishing optimal candidates for primary tumor resection in patients with metastatic lung adenocarcinoma: A predictive model based on propensity score matching.

Yuying Qi, Xiaojin Guo, Zijie Li, Bingzhang Ren, Zhiyu Wang

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yuying QiFourth Hospital of Hebei Medical University, Qiao Dong Qu, Shi Jia Zhuang Shi, He Bei Sheng, 050010, China.
Xiaojin GuoFourth Hospital of Hebei Medical University, Qiao Dong Qu, Shi Jia Zhuang Shi, He Bei Sheng, 050010, China.
Zijie LiFourth Hospital of Hebei Medical University, Qiao Dong Qu, Shi Jia Zhuang Shi, He Bei Sheng, 050010, China.
Bingzhang RenFourth Hospital of Hebei Medical University, Qiao Dong Qu, Shi Jia Zhuang Shi, He Bei Sheng, 050010, China.
Zhiyu WangFourth Hospital of Hebei Medical University, Qiao Dong Qu, Shi Jia Zhuang Shi, He Bei Sheng, 050010, China.
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary tumor resection is associated with survival benefits in patients with metastatic lung adenocarcinoma (mLUAD). However, there are no established methods to determine which individuals would benefit from surgery. Therefore, we developed a model to predict the patients who are likely to benefit from surgery in terms of survival. Methods: Data on patients with mLUAD were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Depending on whether surgery was performed on the primary tumor, patients were categorized into two groups: cancer-directed surgery (CDS) and no-cancer-directed surgery (No-CDS). Propensity Score Matching (PSM) was utilized to address bias between the CDS and No-CDS groups. The prognostic impact of CDS was assessed using Kaplan-Meier analysis and Cox proportional hazard models. Subsequently, we constructed a nomogram to predict the potential for surgical benefits based on multivariable logistic regression analysis using preoperative factors. Results: A total of 89,039 eligible patients were identified, including 6.4% (5705) who underwent surgery. Following PSM, the CDS group demonstrated a significantly longer median overall survival (mOS) compared with the No-CDS group (23 [21-25] vs. 7 [7-8] months; Conclusions: A practical nomogram was developed to identify optimal CDS candidates among patients with mLUAD.

Indexed as

Metastatic lung adenocarcinoma (mLUAD)NomogramPrognosis factorRisk factorSEERSurgery

Identifiers

PMID38690000
PMCPMC11059407
OpenAlexW4393189251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.